{"filings":[{"id":3247117,"accession_number":"0001193125-26-413233","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-10-05T12:45:07+00:00","items":["1.01","2.03","3.03","8.01","5.03","7.01","9.01"],"status":"ready","headline":"Jaguar Health declares Series R preferred dividend, amends royalty and note obligations","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared special one-time dividend of one Series R Convertible Preferred share per common share; record date Oct 13, 2026, payment date Oct 15, 2026.","Series R designates 2,325,000 preferred shares; each converts into 5 common shares on Nov 2, 2026, up to 11,625,000 conversion shares.","Example: 2,281,247 Series R shares would yield 11,406,235 common shares, about 83.3% of outstanding common stock after conversion.","Uptown and Streeterville royalty amendments extend monthly payments from Oct 1, 2026 to Jan 1, 2027; monthly Royalty Payment is greater of $750,000 or actual amount.","2021 Note maturity extended from Oct 1, 2026 to Jan 1, 2027; C/M Capital consented to dividend and Series R authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3110439,"accession_number":"0001193125-26-403356","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-28T11:00:07+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 481,584 shares to Streeterville to cut 2021 Note by $3.4 million","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Jaguar Health entered Sept. 25, 2026 exchange agreements with Streeterville Capital to issue 481,584 common shares for a $3,400,000 reduction of its 2021 Note.","The 2021 Note originally had a principal amount of $6,220,812.50; the exchange leaves the remaining note balance in force.","Shares were issued under Section 3(a)(9) and will be delivered free of restrictive legend, per the exchange agreement.","Jaguar reported about 1,945,542 common shares outstanding as of Sept. 25, 2026, so the exchange shares equal roughly 24.8% of that count.","Streeterville agreed it is not an affiliate and will not beneficially own more than 9.99% after receiving the shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3080965,"accession_number":"0001193125-26-401239","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-24T21:36:19+00:00","items":["1.01","1.02","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health exchanges $6.73M Streeterville debt for 729,989 shares at ~$9.22; 2025 Note fully cancelled","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["2021 Note exchange: issued 182,091 shares to Streeterville for a $1,678,320 reduction of the secured note originally issued Jan. 19, 2021 with a $6,220,812.50 principal.","2025 Note exchange: issued 547,898 shares for a $5,049,909.26 reduction, fully paying off and cancelling the $10,810,000 note issued Nov. 12, 2025.","Implied exchange price of roughly $9.22/share on 729,989 total new shares, versus ~1,463,958 shares outstanding as of Sept. 24, 2026 — about 50% dilution.","Shares delivered via DWAC free of restrictive legends, issued under the Section 3(a)(9) exemption; Streeterville capped at 9.99% beneficial ownership.","Original 2021 Note remains in force for its remaining balance; Streeterville is the noteholder and counterparty, Lisa A. Conte signed as Jaguar CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3053757,"accession_number":"0001193125-26-400087","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-24T10:01:32+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 547,898 shares to cut $5.05M of 2025 Streeterville note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged 547,898 common shares for $5,049,909 reduction in $10.81M secured note to Streeterville Capital.","Shares issued under Section 3(a)(9); no cash paid, shares to become free-trading after Rule 144 holding period tacking.","Post-exchange share count ~1,281,867; issuance adds ~74.6% to prior outstanding stock.","Note reduction represents ~47% of original principal; remaining balance continues under existing terms.","CEO Lisa Conte signed; Streeterville receives unrestricted shares via DWAC delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2992277,"accession_number":"0001193125-26-396752","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-21T20:47:49+00:00","items":["3.03","8.01","5.03","9.01"],"status":"ready","headline":"Jaguar Health effects 1-for-15 reverse stock split, eliminates 14 preferred series","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective Sept 17, 2026; post-split common shares outstanding approx 520,088.","Filed Certificate of Elimination for 14 series of preferred stock with zero shares outstanding.","All eliminated preferred shares had been converted, exchanged, or disposed of prior to Sept 15, 2026.","Preferred shares returned to authorized but undesignated preferred stock; no impact on common equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2874516,"accession_number":"0001193125-26-391682","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-15T17:44:55+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues equity to retire debt and acquire Napo Therapeutics minority stake","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 557,377 shares to Lincoln Alternative to retire 6% convertible note with $175,016.36 balance on Sept 11, 2026.","Exchanged 304,473 total shares to Streeterville for 9.2 Series Q preferred shares across 3 agreements (Jul 7, Sep 11, Sep 14, 2026).","Closed Sep 15 purchase of a shareholder's Napo Therapeutics S.p.A. stake for 535,000 shares plus pre-funded warrant for 2,077,255 shares.","All issuances under Section 3(a)(9) and 4(a)(2) exemptions; shares free of restrictive legends with Rule 144 holding-period tacking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2863516,"accession_number":"0001193125-26-391415","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-15T13:10:08+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Jaguar Health announces 1-for-15 reverse stock split effective Sept 17, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective 12:01 am ET Sept 17, 2026; trading begins split-adjusted on Nasdaq under JAGX.","Split approved by stockholders at April 20, 2026 special meeting; board set exact ratio at 1-for-15.","Purpose is to support compliance with Nasdaq listing standards (minimum bid price requirement).","New CUSIP 47010C854; no fractional shares—cash paid in lieu; Equiniti Trust Company acts as exchange agent.","Outstanding options, warrants, and equity plan reserves adjusted proportionately; par value unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2685765,"accession_number":"0001193125-26-383673","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-09-04T20:15:12+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health special meeting lacks quorum; no vote taken, meeting not reconvened","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Special meeting of stockholders called on September 4, 2026, failed due to insufficient quorum.","No vote was taken on any proposal from the August 3, 2026 proxy statement; no business conducted.","Company will not adjourn or postpone the meeting; it will evaluate calling a new special meeting in the future.","Proposals were not disclosed in this filing; details remain in the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2355358,"accession_number":"0001193125-26-356915","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-08-19T20:15:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.","Net loss attributable to common stockholders $12.69M vs $10.41M; EPS -$15.68 vs -$358.94.","Sales/marketing expense fell $2.5M after Future Pak licensing Jan 12, 2026; cost of product revenue rose to ~$1.0M.","MVID NDA package expected ready end-2026; submission planned Q2 2027; crofelemer MVID data showed parenteral support reduction up to 48%.","Non-GAAP recurring EBITDA loss widened to $8.4M; loss on debt extinguishment $3.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-35.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":21497000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1637399,"accession_number":"0001193125-26-303190","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-07-14T20:15:12+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jaguar Health subsidiary Napo enters new 3-year manufacturing agreement with Alivus for crofelemer supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.","Term from July 9, 2026 to March 31, 2029; replaces prior agreement that expired March 31, 2026.","Includes minimum purchase quantities; shortfall payment obligation if not met.","May be terminated for any reason with 12 months' notice, or for material breach with 90-day cure.","In insolvency, rights assigned to Woodward Specialty LLC (affiliate of Future Pak)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1388836,"accession_number":"0001193125-26-292677","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-07-01T20:34:03+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health completes conversion of Series O Preferred Stock; shares outstanding now 4.86M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 25, 2026, all outstanding Series O Preferred Stock and shares issuable upon Eligible Warrants converted into common stock at 3.209:1 ratio.","Immediately after conversion, common shares outstanding totaled 4,857,211.","Eligible Warrants holders can receive up to 839,000 additional common shares upon exercise.","The Series O Preferred Stock was originally issued as a special one-time dividend on March 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1260237,"accession_number":"0001193125-26-281969","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-25T13:15:57+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health converts Series O Preferred Stock to common at 3.209:1, pays $2.68 for fractions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each share of Series O Preferred Stock converted into 3.209 common shares on June 25, 2026; fractional shares paid in cash at $2.68/share.","Preferred stock was issued as a one-time stock dividend to common stockholders and warrant holders of record March 2, 2026.","Company targeting Breakthrough Therapy designation for crofelemer in MVID with NDA filing planned for H1 2027.","Initial MVID patient in proof-of-concept trial showed up to 37% reduction in parenteral support needs; data presented at ESPGHAN June 2026.","First Amendment to supply agreement with Woodward clarifies inventory title transfer and transition period through Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1195556,"accession_number":"0001193125-26-277570","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K/A","filed_at":"2026-06-22T20:25:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health explores strategic alternatives for crofelemer rare disease program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.","Timing aligns with planned NDA filing for crofelemer in rare intestinal failure diseases (MVID, SBS-IF).","Proof-of-concept trial in MVID/SBS-IF showed up to 37% reduction in parenteral support.","Market research estimates global nutritional support for MVID at ~$1.1B in 2026, rising to ~$1.5B in 2033.","CEO Lisa Conte to present updates at Life Sciences Virtual Investor Forum on June 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1178436,"accession_number":"0001193125-26-276845","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-22T13:17:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.","Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.","Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.","Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.","CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1140800,"accession_number":"0001193125-26-276103","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-18T21:16:09+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health amends royalty agreements to $750k minimum, extends Streeterville debt, exchanges preferred for common","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Royalty amendments: Uptown and Streeterville minimum monthly payment increased to $750k, effective Oct 1, 2026.","Streeterville royalty payment start extended from July 1 to Oct 1, 2026; $6.22M note maturity also extended to Oct 1, 2026.","Exchanged 10.88 shares of Series Q Preferred for 110,249 common shares (three deals June 9, 17, 18).","Aggregate common stock issuance exceeded 5% of outstanding; shares free-trading without legend under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982916,"accession_number":"0001193125-26-266770","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-11T13:00:07+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health secures up to $40M equity line and $2M preferred stock financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.","Single fixed purchase capped at $1.5M; $800K commitment shares to be issued upon registration effectiveness.","Series P preferred stock financing: 240 shares at $10K stated value, 8% annual dividend, mandatory redemption with ELOC proceeds.","Stockholder approval obtained June 8, 2026 allowing issuances beyond 19.99% for both facilities.","Proceeds intended for general corporate purposes; registration statements to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":919516,"accession_number":"0001193125-26-261910","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-08T20:41:08+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health stockholders approve all five proposals, including share issuances up to >19.99% to C/M Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John Micek III elected Class II director with 3,967,085 for, 240,944 withheld.","Ratification of RBSM LLP as auditor approved: 6,898,326 for.","Proposal 3 (ELOC Agreement with C/M Capital) approved: 3,891,273 for, 291,441 against.","Proposal 4 (Preferred Stock Purchase Agreement with C/M Capital, including Series P Preferred) approved: 3,846,847 for.","Proposal 5 (adjournment authority) approved: 3,928,027 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805998,"accession_number":"0001193125-26-253506","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-02T20:10:13+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.","Shares issued under Section 3(a)(9) exemption; no cash consideration exchanged.","Annual meeting reconvened June 2 but further adjourned to June 8 for stockholders to review proxy supplement filed May 29.","Record date remains April 15; stockholders who already voted need not take further action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":678637,"accession_number":"0001193125-26-240645","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-27T13:10:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).","Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.","If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.","CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.","Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611958,"accession_number":"0001193125-26-237195","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-22T21:22:44+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 54k shares to Streeterville in exchange for Series Q preferred; adjourns annual meeting to June 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.","Common shares to be issued without restrictive legend; Streeterville can resell under Rule 144 using tacked holding period from Aug 2022.","Annual Meeting adjourned to June 2, 2026; supplement to proxy to be filed after discussions with Nasdaq staff.","Company plans to provide additional information to stockholders regarding certain proposals in the proxy statement.","Record date remains April 15, 2026 for the reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555516,"accession_number":"0001193125-26-232722","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-20T20:36:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.","Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.","Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.","Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.","Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026."],"consensus_eps_estimate":-2.0808,"consensus_eps_actual":-13.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":20272000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":528996,"accession_number":"0001193125-26-231083","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-19T21:07:21+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.","Streeterville: $3.7M reduction (148 shares) + $6.5M reduction (260 shares).","Series Q carries 10% annual preferred return payable in additional Series Q shares.","Company can exchange Series Q for common at Minimum Price; 9.99% ownership cap.","Restrictive covenants include equity issuance limit and majority-holder consent rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93885,"accession_number":"0001193125-26-211545","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.","Investors exercised pre-funded warrants on May 4, 2026, curing publicly held shares deficiency.","Panel granted one-day extension to May 18, 2026 to show closing bid price >= $1.00 for 10 consecutive days.","Company warns it may not meet the extension terms and could face delisting from Nasdaq.","Non-compliance with bid price rule clock reset after cure of publicly held shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93884,"accession_number":"0001193125-26-204310","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.","Post-split publicly held shares were ~401,226, below the 500,000 requirement.","On May 4, 2026, warrant exercises increased publicly held shares to 513,939.","Company now has 513,974 total shares outstanding; awaiting Nasdaq formal confirmation of compliance.","Reverse split had also triggered continued non-compliance with bid price rule until cure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93883,"accession_number":"0001193125-26-202614","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Jaguar Health receives Nasdaq delisting notice for insufficient publicly held shares after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.","Nasdaq Staff notified company on May 1, 2026 of additional deficiency under Listing Rule 5550(a)(4).","Company must present views to Nasdaq Hearings Panel by May 8, 2026; failure may lead to delisting.","Company remains non-compliant with both minimum bid price and public shares requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93882,"accession_number":"0001193125-26-179391","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["3.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.","Company must close at $1.00+ for at least 10 consecutive business days by May 15.","Reverse stock split at 1-for-35 effective April 30, 2026; trading continues on Nasdaq under JAGX.","Reverse split approved at April 20, 2026 special meeting; no fractional shares – cash in lieu.","Panel retains jurisdiction until September 1, 2026; delisting risk persists if compliance not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93881,"accession_number":"0001193125-26-165120","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health stockholders approve authorized share increase and two reverse stock split proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 298M to 500M shares; total authorized shares from 352M to 554M.","Two reverse stock split proposals approved, each at board-chosen ratio between 1:15 and 1:150.","Issuance of up to $10.81M in shares upon exchange of secured promissory note to Streeterville Capital approved.","All five proposals passed with significant majority; Proposal 1 received 6,031,263 For votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93880,"accession_number":"0001193125-26-149828","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health regains Nasdaq equity compliance after $27M in capital events","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.","Received $16M license fee, $3M buy-back termination, $1M inventory purchase from Woodward/Future Pak.","Also received $2M MSA condition payment, $1.2M firm order, grant revenue, and $0.2M net sales.","Gain of $3.4M on debt extinguishment to Chicago Venture Partners helped restore equity.","Company believes stockholders' equity exceeded $2.5M as of April 7, 2026, curing the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93879,"accession_number":"0001193125-26-144604","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).","Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.","Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.","Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.","Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105860,"accession_number":"0001193125-26-097700","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.","2021 Note maturity extended to July 1, 2026; Outstanding Balance reduced to $6,596,304.11.","2025 Note maturity extended to March 12, 2029; Outstanding Balance reduced to $7,048,021.86.","Warrants for 48,211 shares of common stock terminated via agreement with Uptown, Streeterville, and Iliad.","Napo granted Streeterville security interest in Lechlemer and TDPRV collateral to secure 2025 Note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105859,"accession_number":"0001193125-26-096565","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.","Company ineligible for compliance period due to reverse stock split(s) in prior two years.","Must request appeal by March 12, 2026; intent to timely appeal to Hearings Panel.","Appeal request automatically stays suspension pending hearing outcome; no guarantee of relisting.","Ticker JAGX trades on Nasdaq; delisting would occur if appeal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105858,"accession_number":"0001193125-26-086882","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Jaguar Health files Series O Preferred Stock certificate for special dividend payable March 4","summary_kind":"llm","event_type":"dividend","confidence":"medium","bullets":["Filed Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock.","Special dividend of 1/10th Series O share per common share + each of 2,400,765 eligible warrant shares; record date March 2.","Series O has no dividends, limited voting rights, liquidation preference $0.0001/share, and conversion at Minimum Price by Dec 31, 2026.","Transfer restricted without company consent; conversion limited to 19.99% beneficial ownership cap.","No trading market for Series O; optional conversion by company or automatic conversion on Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105857,"accession_number":"0001193125-26-056157","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["3.03","8.01","7.01","9.01"],"status":"ready","headline":"Jaguar Health Declares Special Stock Dividend to Provide Dilution Protection as It Explores Debt Restructuring","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.","Record date is March 2, 2026; payment date March 4. Each common share receives 0.1 Series O share.","Dividend aims to protect shareholders from dilution as Jaguar explores debt restructuring pathways.","Series O Preferred Stock is non-transferable, has no trading market, and will automatically convert by Dec 31, 2026.","Full conversion at assumed $0.40 price would issue 20.99M shares, diluting non-participating stockholders by 60.65%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105856,"accession_number":"0001193125-26-021064","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.","Exchanged 22 Series L preferred shares (Iliad) and 99.38 shares (Streeterville) for 0.72M and 3.25M pre-funded warrants.","Exchanged 87.78 Series M shares (Iliad) and 69.44 shares (Streeterville) for 2.87M and 2.27M pre-funded warrants.","Warrants exercisable immediately at $0.001/share; no cash received in the exchanges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105855,"accession_number":"0001193125-26-014231","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.","Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.","Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).","Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105854,"accession_number":"0001193125-26-009644","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health closes $350K private placement of 6% notes and warrants for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350K aggregate principal of 6% unsecured promissory notes to accredited investors on Jan 6, 2026.","Notes mature one month from issuance; prepayable without penalty.","Investors received warrants to purchase up to 350K shares at $1.00/share, exercisable for 5 years.","Proceeds used for working capital and general corporate purposes.","Amendment corrects execution and closing dates in original 8-K from Jan 6 to Jan 6 (scrivener's error)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105853,"accession_number":"0001193125-26-009221","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues $350K in 6% notes and warrants for 350K shares at $1.00","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors.","Notes bear 6% annual interest and mature one month from issuance; prepayable without penalty.","Investors received warrants to purchase up to 350,000 shares of common stock at $1.00/share, exercisable immediately for five years.","Proceeds used for working capital and general corporate purposes; transaction closed January 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105852,"accession_number":"0001193125-26-010173","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues $350K in 6% notes with warrants; corrects prior filing dates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350,000 aggregate principal amount of 6% unsecured promissory notes to two accredited investors.","Warrants to purchase up to 350,000 shares at $1.00 per share, exercisable immediately, expire in 5 years.","Proceeds used for working capital and general corporate purposes; transaction closed on January 6, 2026.","This 8-K/A corrects scrivener's errors in the original filing regarding execution and closing dates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122122,"accession_number":"0001193125-25-317693","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.","On Dec 11, exchanged 16 Series M Preferred for 40K common shares and warrant for 304,827 shares at $0.001.","Total 91 Series M Preferred shares cancelled; pre-funded warrants exercisable immediately with 9.99% beneficial ownership blocker.","Transaction executed with Iliad Research and Trading, L.P. via private exchange agreements under Section 3(a)(9).","Issuance reduces preferred liquidation preference; adds ~2.05M fully diluted shares to existing common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122121,"accession_number":"0001193125-25-311294","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).","Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).","Stockholders approved adjournment proposal (2,058,277 For).","Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.","Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122120,"accession_number":"0001193125-25-287650","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.","Note Amendment No. 2 extends maturity of $6.22M secured promissory note to April 1, 2026.","Exchange of 25 Series M Preferred shares for 361,271 common shares; issued unregistered under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122119,"accession_number":"0001193125-25-283139","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.","$8M deposited in restricted account at Lakeside Bank as collateral; release allowed for excess over declining requirement.","Lender can redeem up to $600K/month starting month 12; mandatory prepayment of 25% of upfront IP licensing fees.","Note secured by subsidiary guaranty (JAGX Holdings) and pledge of all its membership interests; strict negative covenants on additional debt and equity.","Proceeds at Company's discretion, including repayment of $6M June 2025 convertible bridge notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122118,"accession_number":"0001193125-25-230298","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Jaguar Health issues 286,532 shares to reduce royalty interest by $600,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 286,532 common shares in exchange for $600,000 reduction in outstanding royalty interest balance.","Exchange agreement entered September 30, 2025 with a holder of royalty interest.","Shares issued under Section 3(a)(9) exemption from registration; form of agreement incorporated by reference.","Transaction reduces debt-like royalty obligation without cash outlay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122117,"accession_number":"0001193125-25-226788","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.","Proceeds to be used for working capital, general corporate purposes, and repayment of existing convertible notes.","Pre-funded warrants exercisable immediately after closing, subject to standard anti-dilution adjustments.","Company committed to file resale registration statement on Form S-3 by October 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138846,"accession_number":"0001193125-25-201351","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.","Series N Preferred non-dividend, non-convertible but exchangeable into common at $1.20 per share after shareholder approval.","Proceeds to be used for working capital and repayment of certain existing notes.","Company must seek stockholder approval within 90 days; beneficial ownership capped at 19.99%.","Registration statement for resale of exchange shares required within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138845,"accession_number":"0001193125-25-183449","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.","Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.","FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).","Company plans to seek license partnerships for orphan indications to generate non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138844,"accession_number":"0001193125-25-180438","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jaguar Health extends ATM manager Lucid's term to Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sixth ATM Amendment extends Lucid Capital Markets' service as manager from June 30 to Dec 31, 2025.","After Dec 31, 2025, Ladenburg Thalmann becomes sole manager unless further extended.","Company filed a prospectus supplement and reimburses Ladenburg $2,500 for legal fees.","No other changes to the existing ATM agreement; all other terms remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156328,"accession_number":"0001193125-25-152345","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.","Issued 90 shares of Series M Preferred to Streeterville for $2.25M reduction in August 2022 royalty interest.","Series M Preferred has $25,000 stated value, no dividends, and accrues a preferred return (10%-6% declining).","Company may exchange Series M shares for common stock at the lower of closing or 5-day average price.","Preferred holders gain consent rights over equity issuances, asset sales, and reverse splits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156327,"accession_number":"0001193125-25-145742","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health extends $2.57M convertible note maturity to Jan 30, 2026; issues new warrants at $2.70 strike","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.","Replacement Notes convertible at $5.535/sh (non-insider) or $5.555/sh (insider); New Warrants exercisable at $2.70/sh, expire in 18 months.","Insiders including CEO and board members participated in exchange, acquiring $492,012 principal of Replacement Notes and warrants for 177,138 shares.","Prior to extension, five investors converted $0.866M of original notes into equity.","Net proceeds from equity/debt financings or licensing above $8M must be used to repay Replacement Notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156326,"accession_number":"0001193125-25-124500","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Jaguar Health raises ~$1.5M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 246,306 shares at $6.09/share; gross proceeds ~$1.5M.","Concurrent private placement of warrants to buy up to 492,612 shares at $5.84, expiring in 24 months.","H.C. Wainwright serves as placement agent; fees: 7% cash, 6% warrant coverage (14,778 warrants at $7.6125).","Net proceeds for working capital, operating expenses, and repayment of outstanding convertible notes.","Closing expected May 22, 2025; shares offered under effective S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-05-22T23:59:59+00:00|156326"}